Navigation Links
Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism

OMAHA, Neb., Feb. 24 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) announced today that it has licensed on an exclusive U.S. basis intellectual property from IntegraGen SA that will enable Transgenomic to develop and commercialize a genetic test designed to assess the risk of autism in children who have older siblings diagnosed with an autism spectrum disorder.  Under the agreement Transgenomic will develop the test in the Company's CAP-accredited and CLIA-certified laboratory, and anticipates launching the new test in the second quarter of 2010.  Financial terms of the agreement were not disclosed.

"We are pleased to have the opportunity to develop and offer a genetic test to clinicians and parents that will assist in the evaluation of children who are thought to be at high risk of being autistic," stated Craig Tuttle, president and chief executive officer of Transgenomic. "We believe that the use of this test in conjunction with standard diagnostic tools will allow for the earlier diagnosis of autism, and importantly, the more timely initiation of treatment plans for these children.  We look forward to adding this proprietary test to our growing commercial offerings."

Autism is a developmental disorder that causes significant social, communication and behavioral challenges in children.  The Centers for Disease Control and Prevention estimates that one in 110 children in the U.S. has an autism-related disorder, and that the incidence of autism is up 57 percent from 2002 to 2006.  Even though parents typically express concerns about their child's developmental progress before the age of three, the average age of diagnoses is not until 53 months.  Early intervention has been shown to be effective in improving a child's ability to develop into a competent adult.  Children with a sibling who has been diagnosed with autism are at a significantly greater risk of developing the disorder.

"IntegraGen is excited about the opportunity for our technology to be commercialized by Transgenomic," said Dr. Bernard Courtieu, chief executive officer of IntegraGen. "We will continue our gene discovery efforts to further our understanding of autism while focusing on other diseases where molecular tests may help with patient diagnosis and disease management."

About IntegraGen

IntegraGen ( is a Biotechnology Company dedicated to gene discovery which allows for the development of molecular diagnostics products and services that provide clinicians with new tools to personalize diagnosis, treatment, and therapy. IntegraGen is focused on the prevention and proactive management of complex debilitating diseases, and dedicated to addressing the needs of patients, clinicians, and advocacy groups. IntegraGen's Genetic Services Business also provides state of the art Genotyping Services to the research community. With discovery and intellectual property focused on Autism, Oncology and Metabolism, IntegraGen's Core Strategy is to deliver a portfolio of high-value molecular diagnostic products and services that drive personalized healthcare solutions for complex diseases.

About Transgenomic, Inc.

Transgenomic, Inc. ( ) is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomics analyses. Its product offerings include the WAVE® Systems and associated consumables specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. With broad applicability to genetic research, over 1,475 systems have been shipped to customers in more than 30 countries. The SURVEYOR® Mutation Detection Kits and SURVEYOR Check-It Kit provide reagents and protocols for high sensitivity detection of mutations in DNA. In addition, HANABI automated chromosome harvesting systems improve laboratory productivity with consistent quality compared with manual methods for cytogenetic analyses. Service offerings include the Transgenomic Molecular Laboratory, which provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases. Transgenomic Pharmacogenomics Services is a CRO for pharmacogenomic, translational research and clinical trials.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

SOURCE Transgenomic, Inc.

Back to top



SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Transgenomic Presents at 12th Annual BIO CEO & Investor Conference
2. Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit
3. Transgenomic, Inc. Reports Third Quarter 2009 Results
4. Transgenomic and Power3 Medical Report Identification of Abnormal Serum Proteins in Parkinsons Disease
5. Transgenomic, Inc. Reports Second Quarter 2009 Results
6. Reminder: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast
7. Webcast Alert: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast
8. Transgenomic, Inc. Announces Appointment of New Board Members
9. Transgenomic, Inc. Reports First Quarter 2009 Results
10. Reminder: Transgenomic Inc. Announces First Quarter 2009 Earnings Release Conference Call Webcast
11. Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimers and Parkinsons Diseases at AAN Annual Meeting
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015 Researchers at the ... Institute for Brain Research at MIT have engineered changes ... cut down on "off-target" editing errors. The refined technique ... use of genome editing. Science , ... three of the approximately 1,400 amino acids that make ...
(Date:12/1/2015)... , Dec. 1, 2015 Frost & ... program. This program addresses ways companies can innovate ... --> ... --> ... healthcare, as well as the disrupting factors altering ...
(Date:12/1/2015)... Minn. , Dec. 1, 2015  The Minnesota ... recipient of the 2015 Tekne Award in the Small ... at the Minneapolis Convention ... have played a significant role in developing new technologies ... living around the world. Clostridium difficile ...
(Date:12/1/2015)... , Dec. 1, 2015  CardioCell LLC, a ... stem cells for cardiovascular indications, intends to proceed ... based on recommendations from a Heart Failure Advisory ... Scientific Advisory Board members . In a ... Phase IIa safety and efficacy data from CardioCell,s ...
Breaking Biology Technology:
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... the "Capacitive Fingerprint Sensors - Technology and Patent ... --> --> Fingerprint ... especially in smartphones. The fingerprint sensor vendor Idex forecasts ... sensor units in mobile devices and of the fingerprint ...
(Date:11/19/2015)... YORK , Nov. 19, 2015  Although some ... market is dominated by a few companies, according to ... companies own 51% of the market share of the ... The World Market for Molecular Diagnostic s ... "The market is still controlled by one company ...
(Date:11/17/2015)... , November 17, 2015 Paris ... 2015.   --> Paris from 17 ... DERMALOG, the biometrics innovation leader, has invented the first ... fingerprints on the same scanning surface. Until now two different ... Now one scanner can capture both on the same ...
Breaking Biology News(10 mins):